Emerging company investment for drug development in highly prevalent chronic diseases is shown to be declining over the last decade and low relative to the prevalence and cost of these diseases. This persistence of this trend could have implications for the future output of innovative medicines in these disease areas. The cause for concern is magnified by the impact these chronic disease areas are having on the overall healthcare system in the US, thus it is important that barriers to the therapeutic innovation are identified and removed. An overview of the investment and R&D trends will be provided followed by a discussion with experts on innovative solutions needed to address highly prevalent chronic disease drug development.

Session ID: 545023